Senior Editor

Abelardo Margolles received his Ph.D. in Pharmacy at the University of Santiago de Compostela, Spain, in 1997. After a postdoctoral study at the University of Groningen, The Netherlands (1997 to 2000), he became Staff Scientist at CSIC in 2001. Currently, he holds a Professor position at IPLA-CSIC. He has had the opportunity to carry out his research thanks to competitive grants funded by regional, national and international funding agencies, as well as several contracts with the industry. Since 2016, he is the Scientific Founder of the CSIC start-up MicroViable Therapeutics (www.microviable.com). Over his scientific career, he has developed extensive knowledge of intestinal microbiomes and food microbes, especially focusing on the probiotic benefits of gut bacteria and the cross-talk interaction between gut microbiota and the host. He has published more than 200 scientific manuscripts in high-impact journals such as PNAS-USA or Microbiome, obtained several patents, and is a member of the Spanish Society of Microbiota, Probiotics, and Prebiotics (SEMiPyP). His research activities cover the following fields: (1) Elucidation of the molecular response behind the adaptation phenomena of food and gut bacteria to technological and gastrointestinal stress factors; (2) Development of probiotics with robust phenotypes, adapted to survive under the technological conditions used in the food industry; (3) Clarification of the cross-talk mechanisms involved in the communication between gut bacteria and human cells; (4) Study of gut and food microbiotas (composition and functionality) under different conditions; (5) Novel fermentable substrates from animal and vegetable origin. Abelardo Margolles was nominated among the highly cited researchers in 2021 (Top 1% by citation per field and year by Clarivate Analytics, Web of Science).

Gut microbiome, Food microbiome, Probiotics, Prebiotics, Bifidobacteria